0 citations
P2.04-002 CASPIAN: Phase 3 Study of First-Line Durvalumab ± Tremelimumab + Platinum-Based Chemotherapy vs Chemotherapy Alone in ED-SCLC
Journal of Thoracic Oncology2017Vol. 12(11), pp. S2398–S2398
Citations Over Time
Related Papers
- → Dual Immune Checkpoint Blockade in Hepatocellular Carcinoma: Where do we Stand?(2022)6 cited
- → The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials(2022)3 cited
- → NSABP FC-9: Phase II study of dual immune checkpoint blockade (ICB) with durvalumab (D) plus tremelimumab (T) following palliative hypofractionated radiotherapy (SBRT) in patients (pts) with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) progressing on chemotherapy.(2018)2 cited
- → Effects of liver metastases on efficacy of immune checkpoint blockade in treatment refractory, metastatic colorectal cancer (CRC): CCTG CO.26.(2022)1 cited
- → Abstract 2257: Phase II study of dual immune checkpoint blockade (ICB) with durvalumab (Durva) plus tremelimumab (T) following palliative hypofractionated radiotherapy (SBRT) in patients (pts) with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) progressing on chemotherapy: NSABP FC-9(2019)1 cited